Key result
Novel pharmacological and non-pharmacological treatments for acute heart failure improve acute cardiovascular hemodynamics and symptoms, but have not yet translated into improved survival and have been deleterious in some cases.
Why the study?
Do novel pharmacological and non-pharmacological treatments improve outcomes in patients with acute heart failure?
Do novel pharmacological and non-pharmacological treatments improve outcomes in patients with acute heart failure?
Answers are grounded in this paper and cite their sources.
Despite improvements in hemodynamics and symptoms, novel therapies for acute heart failure have not yet demonstrated a consistent survival benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2017) conducted a review in Acute heart failure. Novel pharmacological and non-pharmacological treatments vs. Standard therapy or placebo was evaluated. Novel pharmacological and non-pharmacological treatments for acute heart failure improve acute cardiovascular hemodynamics and symptoms, but have not yet translated into improved survival and have been deleterious in some cases.
Synapse has enriched 10 related papers. Consider them for comparative context: